On the 24th of January 2020, Navamedic ASA announced that they have entered into an agreement with Alimentary Health to expand the distribution of Alflorex® in the Netherlands and Denmark. Alflorex® is a unique product for irritable bowel syndrome (IBS) and is classified as a medical device. Alflorex® was launched in Denmark in December 2019 and will be launched in the Netherlands in 2H 2020.
Alflorex® for IBS is classified as a medical Class IIb and contains the patented bacterial strain, Bifidobacterium Longum 35624®. The 35624® bacteria culture is clinically proven to reduce symptoms for IBS, including bloating and gas, abdominal pain, diarrhea and constipation. The product is a part of a strategic partnership with PrecisionBiotics Ltd and Navamedic is already distributing Alflorex® to pharmacies in Norway. In addition, Navamedic has the territory rights to launch the product in Iceland.
“We are pleased to announce the agreement with Alimentary Health, expanding our distribution of Alflorex® to the Netherlands, a key growth market for Navamedic. About 10-15% of the population have IBS symptoms, and by introducing Alflorex® in more markets we are contributing to improved quality of life by helping IBS sufferers to take back control of their gut health,” says Kathrine Gamborg Andreassen, CEO of Navamedic.
Gamborg Andreassen further adds; “Expansion of existing products to new geographies proves the attractiveness of Navamedic’s highly scalable market access platform, and is a recognition of our expertise in introducing, positioning and marketing of products across categories. Both the consumer health gastro therapeutic area and the probiotic market is underdeveloped in our markets, and we aim to drive growth in this market with this unique product.”
A leading pharma company with a strong marketing and distribution platform to hospitals and pharmacies in the Nordic and Baltic region as well as an innovative Medtech division.